Galapagos NV entered into a strategic collaboration with NovAliX in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused contract research organization (CRO). The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientation […]
Related Articles
This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here